<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00568646</url>
  </required_header>
  <id_info>
    <org_study_id>MKC-105</org_study_id>
    <nct_id>NCT00568646</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Phase 2 Study of Oral MKC 1, Administered Twice Daily for 14 Consecutive Days in a 28-Day Cycle, in Patients With Unresectable or Metastatic Pancreatic Cancer Who Have Failed at Least One Prior Chemotherapy Regimen in Either the Neoadjuvant, Adjuvant, or First-line Metastatic Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CASI Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CASI Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      To determine the antitumor activity of MKC-1 in patients with unresectable or metastatic&#xD;
      pancreatic cancer who have failed at least one prior chemotherapy regimen in either the&#xD;
      neoadjuvant, adjuvant, or first-line metastatic setting&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective tumor response rate based on tumor measurements according to the RECIST</measure>
    <time_frame>every 8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MKC-1</intervention_name>
    <description>Oral MKC-1 capsules, administered twice daily, for 14 consecutive days, in a 28-day cycles</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide written informed consent and Health Insurance Portability and Accountability&#xD;
             Act authorization for release of protected health information before any study related&#xD;
             assessments&#xD;
&#xD;
          -  Have histologically confirmed pancreatic cancer and measurable disease according to&#xD;
             RECIST&#xD;
&#xD;
          -  Have failed at least one prior chemotherapy regimen in either the neoadjuvant,&#xD;
             adjuvant, or first-line metastatic setting&#xD;
&#xD;
          -  Be at least 18 years of age at the time of consent&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group performance status of 0 or 1&#xD;
&#xD;
          -  Have the following laboratory results, within 10 days before the first MKC 1&#xD;
             administration:&#xD;
&#xD;
               1. Hemoglobin greater than or equal to 9 g/dL&#xD;
&#xD;
               2. Absolute neutrophil count greater than or equal to 1.5 x 109 cells/L&#xD;
&#xD;
               3. Platelet count greater than or equal to 75 x 109 cells/L&#xD;
&#xD;
               4. Serum creatinine less than or equal to 1.5 times the upper limit of normal (ULN)&#xD;
&#xD;
               5. Aspartate transaminase less than or equal to 2.5 times the ULN&#xD;
&#xD;
               6. Serum albumin greater than or equal to 3.0 g/dL&#xD;
&#xD;
               7. Total bilirubin less than or equal to the ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Be a pregnant or breast-feeding woman. Female patients must be postmenopausal,&#xD;
             surgically sterile, or they must agree to use a barrier method of contraception.&#xD;
             Female patients of childbearing potential must have a negative pregnancy test within&#xD;
             the 10 days before the first MKC 1 administration. Male patients must be surgically&#xD;
             sterile or agree to use an acceptable method of contraception.&#xD;
&#xD;
          -  Have known central nervous system metastases unless they are being treated, are&#xD;
             clinically stable, and do not require the use of steroids.&#xD;
&#xD;
          -  Have clinical evidence of significant bowel obstruction, active uncontrolled&#xD;
             malabsorption syndromes, or a history of total gastrectomy.&#xD;
&#xD;
          -  Have uncontrolled hypercalcemia (serum calcium-corrected greater than 12 mg/dL).&#xD;
&#xD;
          -  Have a serious cardiac condition (Class III/IV congestive heart failure according to&#xD;
             New York Heart Association classification) or documented acute myocardial infarction&#xD;
             within the previous 6 months.&#xD;
&#xD;
          -  Have any medical conditions that, in the investigator's opinion, would impose&#xD;
             excessive risk to the patient. These conditions include: infection requiring&#xD;
             parenteral or oral anti-infective treatment or any altered mental status or any&#xD;
             psychiatric condition that would interfere with the understanding of the informed&#xD;
             consent.&#xD;
&#xD;
          -  Have had previous malignancies, unless free of recurrence for at least 5 years except&#xD;
             cured basal cell carcinoma of the skin or carcinoma-in-situ of the uterine cervix.&#xD;
&#xD;
          -  Be receiving treatment with antiretroviral therapy metabolized through CYP3A4&#xD;
             (including indinavir, nelfinavir, ritonavir, and saquinavir, or any other medications&#xD;
             that interfere with CYP3A4).&#xD;
&#xD;
          -  Have, in the opinion of the investigator, any clinically significant existing&#xD;
             toxicities from previous chemotherapy therapies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eunice Kwak, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Faris JE, Arnott J, Zheng H, Ryan DP, Abrams TA, Blaszkowsky LS, Clark JW, Enzinger PC, Hezel AF, Ng K, Wolpin BM, Kwak EL. A phase 2 study of oral MKC-1, an inhibitor of importin-Î², tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Invest New Drugs. 2012 Aug;30(4):1614-20. doi: 10.1007/s10637-011-9708-3. Epub 2011 Jul 29.</citation>
    <PMID>21800081</PMID>
  </results_reference>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>December 4, 2007</study_first_submitted>
  <study_first_submitted_qc>December 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2007</study_first_posted>
  <last_update_submitted>August 3, 2011</last_update_submitted>
  <last_update_submitted_qc>August 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Carolyn Sidor</name_title>
    <organization>Miikana Therapeutics, an EntreMed, Inc. Company</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

